BioSpace News Archive

Drug Development

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

Allakos Inc. today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK).

January 16, 2024
·
6 min read
Elevating Standards: PathKeeper’s Unique Camera and AI Software in Spinal Surgery

Innovative medical technology company PathKeeper Surgical, headquartered in Israel, is reshaping the field of spinal surgery.

January 16, 2024
·
2 min read
Business

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Willow Biosciences Inc. today announced a collaboration with Enterin, Inc. to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).

January 16, 2024
·
4 min read
Deals

Scaling a Personalized Portfolio: restor3d Completes Key Initiative Following Conformis Acquisition

On September 5, 2023, restor3d, Inc. finalized its previously announced acquisition of Conformis, Inc. With this merger complete, there is tremendous opportunity to deliver clinically differentiated and cost-effective solutions across the orthopaedic landscape.

January 16, 2024
·
2 min read
Deals

Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Satellos Bioscience Inc. is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and to list its common shares (the “Common Shares”) on the TSX.

January 16, 2024
·
5 min read
Business

Envision Pharma Group Appoints Life Sciences Industry Veteran Alice Choi as President, Integrated Medical Capabilities and Solutions (IMC)

Envision Pharma Group (Envision) has appointed Alice Choi as President, Integrated Medical Capabilities and Solutions (IMC) and a member of its Executive Leadership Team.

January 16, 2024
·
2 min read
FDA

Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)

Atsena Therapeutics today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ATSN-101, the company’s investigational gene therapy being evaluated in an ongoing Phase I/II clinical trial in patients with Leber congenital amaurosis.

January 16, 2024
·
3 min read
Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss

Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has secured a $9.0 million Series B financing to advance the development of CYR-064 as a potential first-ever treatment for post-viral smell loss (hyposmia).

January 16, 2024
·
4 min read
BioMidwest

Surmodics to Host Virtual Annual Meeting of Shareholders - January 16, 2024

Surmodics, Inc. will hold its Annual Meeting of Shareholders on Thursday, February 8, at 4 p.m. CT (5 p.m. ET), as a virtual meeting.

January 16, 2024
·
1 min read
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot

FSD Pharma Inc., is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions.

January 16, 2024
·
7 min read